About AccuraGen
AccuraGen is a company based in Menlo Park (United States) founded in 2013. AccuraGen has raised $46.9 million across 2 funding rounds from investors including Temasek, Decheng Capital and Detong Capital. AccuraGen offers products and services including Liquid Biopsy Assay and AccuScan Whole-Genome Sequencing. AccuraGen operates in a competitive market with competitors including Guardant Health, GRAIL, Color, Delfi Diagnostics and BillionToOne, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Accuragen, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$46.9 M (USD)
in 2 rounds
-
Latest Funding Round
$40 M (USD), Series B
Jun 01, 2016
-
Investors
Temasek
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AccuraGen
AccuraGen offers a comprehensive portfolio of products and services, including Liquid Biopsy Assay and AccuScan Whole-Genome Sequencing.
Detects genetic alterations in blood for cancer monitoring and therapy selection.
Analyzes cancer signals for minimal residual disease detection in patients.
Funding Insights of AccuraGen
AccuraGen has successfully raised a total of $46.9M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AccuraGen
AccuraGen has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Temasek, Decheng Capital and Detong Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science and technology sectors
|
Locked | Locked | Locked | |
|
An investment platform is provided for diverse sectors and geographies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for AccuraGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AccuraGen
Investment portfolio details for AccuraGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AccuraGen
Detailed financials for AccuraGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Accuragen Comparisons
Peer comparison for AccuraGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AccuraGen
AccuraGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Color, Delfi Diagnostics and BillionToOne, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
Detailed competitors of AccuraGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Accuragen
Complete news archive for AccuraGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AccuraGen
AccuraGen was founded in 2013 and raised its 1st funding round 2 years after it was founded.
AccuraGen is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
AccuraGen is a funded company, having raised a total of $46.9M across 2 funding rounds to date.
AccuraGen was founded in 2013 and is based in Menlo Park, United States. Operations focus on the biotechnology sector, where non-invasive diagnostics for cancer are created. Proprietary CLAmp-seq technology, based on single-strand DNA sequencing, is employed to identify circulating cell-free tumor DNA in patient samples. This approach supports early detection efforts without invasive procedures.
AccuraGen's top competitors include Guardant Health, GRAIL and BillionToOne.
AccuraGen offers Liquid Biopsy Assay and AccuScan Whole-Genome Sequencing.
AccuraGen has 6 investors. Key investors include Temasek, Decheng Capital, Detong Capital, StartX, and Yifang Ventures.